Literature DB >> 34021191

Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorder using optical coherence tomography angiography.

Małgorzata Rogaczewska1, Sławomir Michalak2, Marcin Stopa3.   

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) are autoimmune demyelinating diseases of distinct etiology presenting with optic neuritis (ON). This study aimed to identify the macular and peripapillary neurovascular alterations that may facilitate the differentiation between NMOSD and MS eyes using spectral-domain optical coherence tomography (OCT) and OCT angiography (OCTA). A total of 13 NMOSD patients and 40 MS patients were evaluated. After ON, the radial peripapillary capillary (RPC) vessel density was significantly decreased in the superior (S) and inferior (I) sectors in NMOSD compared with MS eyes, whereas in non-ON eyes, the temporal (T) sector of RPC was reduced in MS group. In the ON eyes, the retinal nerve fiber layer in the I and T quadrants was thinner in NMOSD than in MS. Regarding ON and non-ON eyes, the macular capillary plexuses, and the ganglion cell complex thickness did not differ between NMOSD and MS. The ratios, based on the disease-specific intra-eye RPC vessel density reduction pattern, were the best discriminants between NMOSD and MS, i.e., inferior to nasal (I/N) and I/T ratios for ON eyes, and S/T and N/T ratios for non-ON eyes. Our results show that the OCTA-based simple ratios may be useful in distinguishing NMOSD and MS patients.

Entities:  

Year:  2021        PMID: 34021191     DOI: 10.1038/s41598-021-90036-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  7 in total

Review 1.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

2.  Differential patterns of parafoveal and peripapillary vessel density in multiple sclerosis and neuromyelitis optica spectrum disorder.

Authors:  Ga-In Lee; Kyung-Ah Park; Sei Yeul Oh; Ju-Hong Min; Byoung Joon Kim
Journal:  Mult Scler Relat Disord       Date:  2021-01-19       Impact factor: 4.339

3.  Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis.

Authors:  Elisa Schneider; Hanna Zimmermann; Timm Oberwahrenbrock; Falko Kaufhold; Ella Maria Kadas; Axel Petzold; Frieder Bilger; Nadja Borisow; Sven Jarius; Brigitte Wildemann; Klemens Ruprecht; Alexander U Brandt; Friedemann Paul
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

4.  Detailed Vascular Anatomy of the Human Retina by Projection-Resolved Optical Coherence Tomography Angiography.

Authors:  J P Campbell; M Zhang; T S Hwang; S T Bailey; D J Wilson; Y Jia; D Huang
Journal:  Sci Rep       Date:  2017-02-10       Impact factor: 4.379

Review 5.  The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.

Authors:  Michalina Jasiak-Zatonska; Alicja Kalinowska-Lyszczarz; Slawomir Michalak; Wojciech Kozubski
Journal:  Int J Mol Sci       Date:  2016-03-02       Impact factor: 5.923

6.  The Detection of Retina Microvascular Density in Subclinical Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders.

Authors:  Yihong Chen; Ce Shi; Lili Zhou; Shenghai Huang; Meixiao Shen; Zhiyong He
Journal:  Front Neurol       Date:  2020-02-11       Impact factor: 4.003

  7 in total
  2 in total

Review 1.  Optical Coherence Tomography and Optical Coherence Tomography with Angiography in Multiple Sclerosis.

Authors:  Ioannis-Nikolaos Chalkias; Christos Bakirtzis; Demetrios Pirounides; Marina Kleopatra Boziki; Nikolaos Grigoriadis
Journal:  Healthcare (Basel)       Date:  2022-07-25

Review 2.  What's new in neuromyelitis optica spectrum disorder treatment?

Authors:  Yi-Ching Chu; Tzu-Lun Huang
Journal:  Taiwan J Ophthalmol       Date:  2022-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.